Takeda Completes $6 Billion Acquisition of Nimbus Therapeutics Subsidiary
Takeda’s acquisition of Nimbus Lakshmi will grant them rights to NDI-034858, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases.
Takeda and Nimbus Therapeutics, a clinical-stage pharmaceutical company, announced the completion of an acquisition agreement on Feb. 8, 2023. Announced in December 2022, the agreement includes Takeda’s acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor TAK-279, formerly known as NDI-034858. Four billion dollars were paid upfront, with two additional billion-dollar payments to be made contingent on TAK-279 reaching net sales of $4 and $5 billion, respectively.
According to a company press release, TAK-279 is being evaluated for psoriasis as well as multiple other immune-mediated diseases. Takeda is expected to present Phase IIb data in the fourth quarter of the 2022 fiscal year, while a Phase III study in psoriasis is expected to begin sometime in 2023.
“With our plan to acquire announced in December [2022], we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline,” said Ramona Sequeira, president, global portfolio division, Takeda, in the release. “This program closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”
Source: Takeda
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
